For example, promising clinical outcome was achieved by PARP1 inhibitor olaparib in combination with chemotherapeutic agent temozolomide in relapsed SCLC, presenting a great improvement compared to the modest response induced by DDR inhibitors as a single agent.19 This evidence concerns the gene PARP1 and small cell lung carcinoma.